[go: up one dir, main page]

AR035218A1 - Inhibidores vla-4 - Google Patents

Inhibidores vla-4

Info

Publication number
AR035218A1
AR035218A1 ARP010106105A ARP010106105A AR035218A1 AR 035218 A1 AR035218 A1 AR 035218A1 AR P010106105 A ARP010106105 A AR P010106105A AR P010106105 A ARP010106105 A AR P010106105A AR 035218 A1 AR035218 A1 AR 035218A1
Authority
AR
Argentina
Prior art keywords
group
substituted
unsubstituted
atom
hydrogen atom
Prior art date
Application number
ARP010106105A
Other languages
English (en)
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Publication of AR035218A1 publication Critical patent/AR035218A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Un compuesto representado por la siguiente fórmula (1) [donde, W representa WA-A1-WB- (en el cual WA representa un grupo arilo sustituido o no sustituido o un grupo heterocíclico monovalente sustituido o no sustituido, A1 representa -NR1-, un enlace simple, -C(O)-, -C(O)NR1-, un grupo vinileno sustituido o no sustituido, un grupo etinileno, -CR1aR1b-O-, -CR1a=CR1b-C(O)NR1- o CR1a=CR1b-C(O)-(en el cual R1 representa un átomo de hidrógeno o un grupo alquilo inferior, y R1a y R1b, cada uno representa de manera independiente un átomo de hidrógeno o un grupo alquilo inferior), WB representa un grupo arileno sustituido o no sustituido o un grupo heterocíclico divalente sustituido); R representa un enlace simple, -NH-, -OCH2-, un grupo alquenileno o -(CH2)n-(en el cual, n representa 1 o 2); X representa -C(O)-, -CH2 - o -S(O)2-, y M representa la siguiente fórmula (3), (4) o (5): en la cual (3a) representa un grupo heterocíclico divalente de 4, 5 o 6 miembros (en el cual el átomo de nitrógeno está unido a X y Q representa un átomo de carbono, azufre oxígeno o nitrógeno), R11, R12 y R13 cada uno representa de manera independiente un átomo de hidrógeno, un grupo hidroxilo, un grupo amino, un átomo de halógeno, un grupo ciano, un grupo carboxilo, un grupo alcoxicarbonilo, un grupo carbamoilo, un grupo mono- o dialquilaminocarbonilo sustituido o no sustituido, un grupo alquilo sustituido o no sustituido, un grupo arilo sustituido o no sustituido, un grupo heteroarilo sustituido o no sustituido, un grupo alcoxi sustituido o no sustituido, un grupo mono- o dialquilamino sustituido o no sustituido, un grupo cicloalquilamino sustituido o no sustituido, un grupo alquilsulfonilamino sustituido o no sustituido, un grupo arilsulfonilamino sustituido o no sustituido, un grupo ariloxi, sustituido o no sustituido, un grupo heteroariloxi sustituido o no sustituido, y un grupo benciloxi sustituido o no sustituido, un grupo alquiltio sustituido o no sustituido, un grupo cicloalquiltio sustituido o no sustituido, un grupo ariltio sustituido o no sustituido, un grupo alquilsulfonilo sustituido o no sustituido, un grupo cicloalquilsulfonilo sustituido o no sustituido, o un grupo arilsulfonilo sustituido o no sustituido, o R11, R13 o R12 y R13 se pueden acoplar para formar, junto con el átomo que constituye el grupo heterocíclico al que R12 a R13 están unidos, un hidrocarburo cíclico o heterociclo de 3 a 7 miembros (el hidrocarburo cíclico y el heterociclo pueden tener de 1 a 3 sustituyentes seleccionados de un grupo hidroxilo, átomos de halógeno, un grupo amino, grupos alquilo, grupos alcoxi, grupos arilo, grupos ariloxi, grupos alquilamino, un grupo benciloxi y grupos heteroarilo). R14 representa un átomo de hidrógeno o un alquilo inferior sustituido o no sustituido, Y representa un enlace simple, -C(O)-, -C(O)NH-, o un grupo hidrocarburo alifático divalente lineal o ramificado de C1-12 que puede tener un anillo espiro de C3-6 o puede tener por los menos un -O-, -S-, -S(O)2-, -C(O)- o -NY1- (en la cual Y1 representa un átomo de hidrógeno o un grupo alquilo inferior) en el grupo funcional hidrocarburo en reemplazo del átomo de carbono, Z representa un grupo arileno sustituido o no sustituido, un grupo heteroarileno sustituido o no sustituido o un grupo cicloalquileno sustituido o no sustituido, A2 representa un enlace simple, un grupo alquenileno, un grupo alquinileno, -(CH2)t - o -O(CH2)v-, (en el que t representa 1, 2 o 3 y v representa 0, 1, 2, o 3), y R10 representa un grupo hidroxilo o un grupo alcoxi inferior) de fórmula (4), en el cual fórmula (4a) representa un grupo heterocíclico divalente de 4, 5, 6 o 7 miembros (en el cual el átomo de nitrógeno está unido a X y Q1 representa un átomo de carbono, azufre, oxígeno o nitrógeno), R15 y R16 cada uno representa de manera independiente un átomo de hidrógeno, un grupo hidroxilo, un átomo de halógeno, un grupo amino, un grupo alquilo sustituido o no sustituido o un grupo alcoxi, R16a representa un átomo de hidrógeno o un grupo alquilo sustituido o no sustituido; Y3 representa -O-, -S-, -S(O)2-, -(CH2)fO-, o -NY4- (en la cual f representa 1, 2 o 3 e Y4 representa un átomo de hidrógeno o un grupo alquilo inferior), Z1 representa un grupo arileno sustituido o no sustituido, un grupo heteroarileno sustituido o no sustituido o un grupo cicloalquileno sustituido o no sustituido, A3 representa un enlace simple, un grupo alquenileno, un grupo alquinileno, -(CH2)e- (en el que, e representa 1, 2, o 3), y R17 representa un grupo hidroxilo o un grupo alcoxi inferior), (fórmula 5) (en la cual R18 representa -NR20-(en la cual R20 representa un átomo de hidrógeno, un grupo alquilo sustituido o no sustituido, un grupo cicloalquilo sustituido o no sustituido, un grupo arilo sustituido o no sustituido, un grupo bencilo sustituido o no sustituido, un grupo alquenilo inferior sustituido o no sustituido o un grupo alquinilo sustituido o no sustituido), Z2 representa un grupo hidrocarbonado alifático divalente lineal o ramificado de C1-12 que puede tener un anillo espiro de C3-6, puede tener por lo menos un grupo cicloalquileno de C3-6 en el grupo hidrocarbonado en reemplazo del átomo de carbono o puede tener por lo menos un -O-, -S-, -S(O)2-, -C(O)- o -NR21-(en la cual R21 representa un átomo de hidrógeno o un grupo alquilo inferior sustituido o no sustituido en el grupo funcional hidrocarburo en reemplazo del átomo de carbono, Q2 representa un enlace simple, un grupo arileno sustituido o no sustituido, un grupo heteroarileno sustituido o no sustituido o un grupo cicloalquileno sustituido o no sustituido, L representa un enlace simple, o un grupo alquileno inferior sustituido o no sustituido o un grupo alquinileno inferior sustituido o no sustituido, o R19 representa un grupo hidroxi o un grupo alcoxi inferior)]; o una sal del mismo. Un producto farmacéutico que comprende un compuesto de fórmula (1) o sal del mismo, útil como preventivo o remedio de una enfermedad causada por adhesión celular que se selecciona entre enfermedades inflamatorias, autoinmunes, metástasis, asma bronquial, rinostenosis, diabetes, artritis, psoriasis, esclerosis múltiple, enfermedades intestinales inflamatorias y rechazo al trasplante. Una composición farmacéutica que comprende un vehículo farmacéuticamente aceptable y un compuesto de fórmula (1) o su sal.
ARP010106105A 2000-12-28 2001-12-28 Inhibidores vla-4 AR035218A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000402890 2000-12-28
JP2001149923 2001-05-18

Publications (1)

Publication Number Publication Date
AR035218A1 true AR035218A1 (es) 2004-05-05

Family

ID=26607210

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010106105A AR035218A1 (es) 2000-12-28 2001-12-28 Inhibidores vla-4

Country Status (16)

Country Link
US (1) US7157487B2 (es)
EP (1) EP1346982B1 (es)
JP (1) JP4212358B2 (es)
KR (1) KR100884877B1 (es)
CN (1) CN100471838C (es)
AR (1) AR035218A1 (es)
AT (1) ATE524441T1 (es)
AU (1) AU2002219555B2 (es)
BR (1) BR0116608A (es)
CA (1) CA2430978C (es)
IL (1) IL156064A0 (es)
MX (1) MXPA03005838A (es)
NO (1) NO326014B1 (es)
RU (1) RU2290403C2 (es)
TW (1) TWI312779B (es)
WO (1) WO2002053534A1 (es)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0031315D0 (en) * 2000-12-21 2001-02-07 Glaxo Group Ltd Indole derivatives
ATE447404T1 (de) 2002-03-29 2009-11-15 Novartis Vaccines & Diagnostic Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
ATE374768T1 (de) * 2002-10-03 2007-10-15 Hoffmann La Roche Indole-3-carbonsaüreamide als glucokinase (gk) aktivatoren
US20070066577A1 (en) * 2003-04-03 2007-03-22 Hea Young Park Choo Benzoxazole derivative or analogue thereof for inhibiting 5-lipoxygenase and pharmaceutical composition containing same
JPWO2004099136A1 (ja) * 2003-05-09 2006-07-13 第一製薬株式会社 ピロリジン誘導体の製造方法
EP1479675A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
WO2005009992A1 (ja) 2003-07-24 2005-02-03 Daiichi Pharmaceutical Co., Ltd. シクロヘキサンカルボン酸類
US6984652B2 (en) 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
EP1698621A4 (en) * 2003-12-26 2008-11-19 Daiichi Seiyaku Co PROCESS FOR PREPARING A PYRROLIDINE DERIVATIVE
JPWO2005063678A1 (ja) * 2003-12-26 2007-12-20 第一三共株式会社 フェニル酢酸誘導体の製造方法
BRPI0509150B8 (pt) * 2004-03-24 2021-05-25 Jerini Ag compostos para a inibição de angiogênese e uso destes
JP2005350417A (ja) * 2004-06-11 2005-12-22 Dai Ichi Seiyaku Co Ltd 還元的エーテル化法を用いたピロリジン誘導体の製造法
TW200610754A (en) * 2004-06-14 2006-04-01 Daiichi Seiyaku Co Vla-4 inhibitor
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EP1771169A1 (en) 2004-07-14 2007-04-11 PTC Therapeutics, Inc. Methods for treating hepatitis c
JP2008507518A (ja) 2004-07-22 2008-03-13 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するためのチエノピリジン
JP2006056830A (ja) * 2004-08-20 2006-03-02 Dai Ichi Seiyaku Co Ltd ２−アリールアミノベンゾオキサゾール誘導体
WO2006068760A2 (en) * 2004-11-19 2006-06-29 The Regents Of The University Of California Anti-inflammatory pyrazolopyrimidines
US8097610B2 (en) * 2005-08-26 2012-01-17 Shionogi & Co., Ltd. Derivative having PPAR agonistic activity
US8129366B2 (en) 2005-12-13 2012-03-06 Daiichi Sankyo Company, Limited VLA-4 inhibitory drug
CA2909277A1 (en) 2006-04-04 2007-10-11 Kevan M. Shokat Kinase antagonists
DE102006021878A1 (de) * 2006-05-11 2007-11-15 Sanofi-Aventis Phenylamino-benzoxazol substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7858645B2 (en) * 2006-11-01 2010-12-28 Hoffmann-La Roche Inc. Indazole derivatives
WO2009046448A1 (en) * 2007-10-04 2009-04-09 Intellikine, Inc. Chemical entities and therapeutic uses thereof
DK2240451T3 (da) 2008-01-04 2017-11-20 Intellikine Llc Isoquinolinonderivater substitueret med en purin, der er anvendelig som pi3k-inhibitorer
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
EP2252293B1 (en) * 2008-03-14 2018-06-27 Intellikine, LLC Kinase inhibitors and methods of use
US9096611B2 (en) 2008-07-08 2015-08-04 Intellikine Llc Kinase inhibitors and methods of use
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
US8697709B2 (en) 2008-10-16 2014-04-15 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
MX2011006503A (es) 2008-12-19 2011-09-06 Vertex Pharma Derivados de pirazina utiles como inhibidores de la cinasa de atr.
TW201035088A (en) 2009-02-27 2010-10-01 Supergen Inc Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
EP2427195B1 (en) 2009-05-07 2019-05-01 Intellikine, LLC Heterocyclic compounds and uses thereof
CN102573480B (zh) 2009-06-09 2015-06-10 加利福尼亚资本权益有限责任公司 三嗪衍生物及其治疗应用
KR20120018224A (ko) 2009-06-09 2012-02-29 아브락시스 바이오사이언스, 엘엘씨 헷지호그 신호전달 억제제로서의 이소퀴놀린, 퀴놀린 및 퀴나졸린 유도체
KR20120026612A (ko) 2009-06-09 2012-03-19 아브락시스 바이오사이언스, 엘엘씨 벤질 치환 트리아진 유도체와 이들의 치료적 용도
WO2011020874A1 (en) 2009-08-20 2011-02-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
US8722720B2 (en) 2009-10-28 2014-05-13 Newlink Genetics Corporation Imidazole derivatives as IDO inhibitors
EP2571357B1 (en) 2010-05-21 2016-07-06 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
DK2663309T3 (en) 2011-01-10 2017-06-19 Infinity Pharmaceuticals Inc METHODS FOR PRODUCING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES
EP2678018A4 (en) 2011-02-23 2015-09-30 Intellikine Llc COMBINATION OF CHINESE HEMMER AND USES THEREOF
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR20140063605A (ko) 2011-07-19 2014-05-27 인피니티 파마슈티칼스, 인코포레이티드 헤테로사이클릭 화합물 및 그의 용도
AR091790A1 (es) 2011-08-29 2015-03-04 Infinity Pharmaceuticals Inc Derivados de isoquinolin-1-ona y sus usos
MX370814B (es) 2011-09-02 2020-01-08 Univ California Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
AU2013323426A1 (en) 2012-09-26 2015-04-23 The Regents Of The University Of California Modulation of ire1
KR102229478B1 (ko) 2012-11-01 2021-03-18 인피니티 파마슈티칼스, 인코포레이티드 Pi3 키나아제 동형단백질 조절인자를 사용하는 암의 치료
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
PL3052485T3 (pl) 2013-10-04 2022-02-28 Infinity Pharmaceuticals, Inc. Związki heterocykliczne i ich zastosowania
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2943075C (en) 2014-03-19 2023-02-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3214936A1 (en) * 2014-11-06 2017-09-13 Basf Se 3-pyridyl heterobicyclic compound for controlling invertebrate pests
HRP20200064T1 (hr) 2015-06-09 2020-04-03 Abbvie Inc. Modulatori nuklearnih receptora (ror) namijenjeni liječenju upalnih i autoimunih bolesti
NZ740616A (en) 2015-09-14 2023-05-26 Infinity Pharmaceuticals Inc Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
IL263680B2 (en) 2016-06-24 2025-10-01 Infinity Pharmaceuticals Inc PI3K inhibitors for use in combination with a second therapeutic agent for the treatment, management or prevention of cancer
JP7189368B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリンの阻害のための化合物
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
KR102630416B1 (ko) 2018-10-30 2024-02-01 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 퀴놀린 유도체
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
CN114222730B (zh) 2019-08-14 2024-09-10 吉利德科学公司 用于抑制α4β7整合素的化合物
AU2021289665A1 (en) 2020-06-10 2022-12-15 Aligos Therapeutics, Inc. Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections
US20240301512A1 (en) 2021-01-29 2024-09-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists
IL309732A (en) 2021-07-09 2024-02-01 Aligos Therapeutics Inc Antiviral compounds
WO2023043816A1 (en) 2021-09-17 2023-03-23 Aligos Therapeutics, Inc. Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
DE2500157C2 (de) * 1975-01-03 1983-09-15 Hoechst Ag, 6230 Frankfurt N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung
DE2706977A1 (de) * 1977-02-18 1978-08-24 Hoechst Ag Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung
US4184658A (en) 1978-02-13 1980-01-22 General Electric Company Cushion mount for prime mover
DE3063878D1 (en) * 1979-07-13 1983-07-28 Thomae Gmbh Dr K Derivatives of carboxylic acids, their preparation and medicaments containing them
JPS60181081A (ja) 1984-02-29 1985-09-14 Kaken Pharmaceut Co Ltd 新規ビスベンゾフラニルケトン誘導体
JPH04112868A (ja) 1990-09-03 1992-04-14 Otsuka Pharmaceut Co Ltd 置換ヘテロ環を有するフェニルカルボン酸誘導体
JPH0543574A (ja) 1991-08-13 1993-02-23 Wakamoto Pharmaceut Co Ltd ヘテロ環置換テトラゾール−１−酢酸誘導体
FR2694295B1 (fr) * 1992-07-28 1994-09-02 Adir Nouveaux peptides dérivés de trifluoromethylcetones, leur procéde de préparation et les compositions pharmaceutiques qui les contiennent.
US5821231A (en) 1993-12-06 1998-10-13 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using same
ES2103181B1 (es) * 1994-08-01 1998-04-01 Menarini Lab Amidas naftalenicas con accion antagonista de los leucotrienos.
GB9408936D0 (en) * 1994-05-05 1994-06-22 Cancer Res Inst Anti-cancer compounds
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
JPH10512585A (ja) 1995-06-30 1998-12-02 スミスクライン・ビーチャム・コーポレイション 赤血球形成を増強するためのｓｔａｔ ５ ｓｈ２領域特異性化合物の使用
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
ES2271971T3 (es) * 1996-07-25 2007-04-16 Biogen Idec Ma Inc. Inhibidores de la adhesion celular.
AU717430B2 (en) * 1996-08-26 2000-03-23 Genetics Institute, Llc Inhibitors of phospholipase enzymes
DE19647381A1 (de) 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
US6117901A (en) * 1996-11-22 2000-09-12 Athena Neurosciences, Inc. N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for use
JP2001505204A (ja) * 1996-11-22 2001-04-17 エラン・ファーマシューティカルズ・インコーポレイテッド Ｎ―（アリール／ヘテロアリールアセチル）アミノ酸エステル、それを含有する医薬組成物および該化合物を用いてβ―アミロイドペプチドの放出および／または合成を阻害する方法
AU747907B2 (en) 1997-12-23 2002-05-30 Aventis Pharma Limited Substituted beta-alanines
EA200000873A1 (ru) * 1998-02-25 2001-04-23 Дженетикс Инститьют, Инк. Ингибиторы фосфолипазы a
ATE256659T1 (de) * 1998-05-28 2004-01-15 Biogen Inc Ein vla-4-inhibitor: omepupa-v
CN1311771A (zh) * 1998-06-08 2001-09-05 味之素株式会社 苯甲脒衍生物
NZ508033A (en) 1998-06-30 2002-12-20 Pfizer Prod Inc Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
GB9916374D0 (en) 1998-07-23 1999-09-15 Zeneca Ltd Chemical compounds
JP2002521375A (ja) * 1998-07-23 2002-07-16 アストラゼネカ アクチエボラーク 化合物
IL141596A0 (en) 1998-08-26 2002-03-10 Aventis Pharma Ltd Aza-bicycles which modulate the inhibition of cell adhesion
GB9821199D0 (en) 1998-09-30 1998-11-25 Glaxo Group Ltd Chemical compounds
US6207700B1 (en) 1999-01-07 2001-03-27 Vanderbilt University Amide derivatives for antiangiogenic and/or antitumorigenic use
ES2263447T3 (es) 1999-02-16 2006-12-16 Aventis Pharma Limited Compuestos biciclicos y su uso como ligandos en los receptores de integrinas.
JP2000344666A (ja) 1999-04-01 2000-12-12 Sankyo Co Ltd 糖及び脂質代謝改善剤
SK14372001A3 (sk) 1999-04-12 2002-06-04 Aventis Pharma Limited Substituované bicyklické heteroarylové zlúčeniny ako antagonisty integrínu a farmaceutický prostriedok, ktorý ich obsahuje
EP1177181B1 (en) 1999-05-05 2009-01-28 Aventis Pharma Limited Substituted bicyclic compounds
ES2257296T3 (es) 1999-05-05 2006-08-01 MERCK & CO., INC. Nuevas prolinas como agentes antimicrobianos.
WO2000068223A1 (en) 1999-05-05 2000-11-16 Aventis Pharma Limited Ureas and their use as cell adhesion modulators
HK1042293A1 (zh) 1999-05-05 2002-08-09 Aventis Pharma Limited 取代的吡咯烷作為細胞粘合抑制物
US6756378B2 (en) * 1999-06-30 2004-06-29 Pharmacopeia Drug Discovery, Inc. VLA-4 inhibitor compounds
AR035011A1 (es) 1999-06-30 2004-04-14 Daiichi Seiyaku Co Compuestos inhibidores de vla-4
ATE343383T1 (de) 1999-08-13 2006-11-15 Biogen Idec Inc Hemmer der zelladhäsion
AU2155001A (en) 1999-11-10 2001-06-06 Aventis Pharma Deutschland Gmbh N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor xa
AU2018301A (en) * 1999-12-28 2001-07-24 Pfizer Products Inc. Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
GB0001346D0 (en) 2000-01-21 2000-03-08 Astrazeneca Uk Ltd Chemical compounds
DE10006453A1 (de) 2000-02-14 2001-08-16 Bayer Ag Piperidylcarbonsäuren als Integrinantagonisten
GB0004686D0 (en) 2000-02-28 2000-04-19 Aventis Pharma Ltd Chemical compounds
WO2001064640A1 (en) 2000-03-01 2001-09-07 Aventis Pharma Limited 2,3-dihydro-1h-indolinyl-alkanoic acids as cell adhesion inhibitors
US6448281B1 (en) * 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
BR0112580A (pt) 2000-07-19 2003-06-17 Hoffmann La Roche Compostos, composições farmacêuticas que contêm os mesmos, utilização desses compostos, processo para tratamento terapêutico e/ou profilático e processo para a preparação desses compostos
GB2377933A (en) 2001-07-06 2003-01-29 Bayer Ag Succinic acid derivatives useful as integrin antagonists

Also Published As

Publication number Publication date
WO2002053534A1 (en) 2002-07-11
AU2002219555B2 (en) 2006-11-30
ATE524441T1 (de) 2011-09-15
NO326014B1 (no) 2008-09-01
EP1346982B1 (en) 2011-09-14
JPWO2002053534A1 (ja) 2004-04-30
RU2290403C2 (ru) 2006-12-27
TWI312779B (es) 2009-08-01
MXPA03005838A (es) 2003-09-10
KR20030067730A (ko) 2003-08-14
RU2003123115A (ru) 2005-03-27
US20040110945A1 (en) 2004-06-10
CN1483024A (zh) 2004-03-17
BR0116608A (pt) 2004-06-29
HK1060726A1 (zh) 2004-08-20
EP1346982A4 (en) 2005-08-10
CA2430978A1 (en) 2002-07-11
KR100884877B1 (ko) 2009-02-23
IL156064A0 (en) 2003-12-23
US7157487B2 (en) 2007-01-02
HK1081545A1 (zh) 2006-05-19
WO2002053534A8 (en) 2002-09-19
JP4212358B2 (ja) 2009-01-21
EP1346982A1 (en) 2003-09-24
CA2430978C (en) 2012-05-15
CN100471838C (zh) 2009-03-25
NO20032994L (no) 2003-08-27
NO20032994D0 (no) 2003-06-27

Similar Documents

Publication Publication Date Title
AR035218A1 (es) Inhibidores vla-4
NO2020003I1 (no) plerixafor (1,1’-[ 1,4-fenylen-bis- (metylen)]- bis1,2,8,11-tetraazacyklotetradekan) eventuelt i form av et farmasøytisk akseptabelt salt eller metallkompleks derav
DE60005504D1 (de) Chinolinderivate als mek enzym-inhibitoren
CA2475432A1 (en) 2,4,6-triamino-1,3,5-triazine derivative
AP1497A (en) Methods and compositions to enhance white blood cell count.
CA2536870A1 (en) Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists
CO5700817A2 (es) Compuesto pentaciclico heteroaromatico y uso medicinal del mismo
AR056327A1 (es) Compuestos de nucleosidos para el tratamiento de infecciones virales
ES2175919T3 (es) Derivados del camptothecin con actividad antitumoral.
NO305318B1 (no) Heterocykliske forbindelser og anvendelser derav
MX2009003927A (es) Derivado espirocetal de tioglucosa y uso del mismo como un agente terapeutico para la diabetes.
EP2845587A3 (en) Melanin production inhibitor
TW200745242A (en) Electret materials
TN2010000173A1 (fr) Antagonistes de cgrp
BR0010324A (pt) Composto, composição farmacêutica, e, método de preparação de um composto
MX2007007428A (es) Compuestos heterociclicos, antagonistas de ccr2b.
AR045791A1 (es) Derivados de triazol sustituidos como antagonistas de oxitocina
ATE517087T1 (de) Cbp-verbindung
UA80814C2 (en) Heterocyclic oxime compounds, a process for their preparation (variants) and pharmaceutical compositions containing them, intermediate
BG103194A (en) Pharmaceutical products for the treatment and prevention of diseases caused by the impairment of the vascular endothelial cells
PE20030611A1 (es) Compuestos basicos lineales que tienen actividad antagonista de nk-2 y sus formulaciones
AR026222A1 (es) Compuestos derivados de acido antranilico
CA2531980A1 (en) Imide derivatives as therapeutic agents for senile dementia
ATE278678T1 (de) Substituierte 1-aza-2-imino-heterocyclen und ihre verwendung als aktivatoren der nikotinergen acetylcholinrezeptoren
UA93489C2 (ru) Гетероциклические соединения kak антагонисты ccr2b

Legal Events

Date Code Title Description
FB Suspension of granting procedure